---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-002903"
form_type: "8-K/A"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2024-01-19T23:59:59+00:00"
generated_at: "2026-06-06T21:03:17.664216+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics reports CEO transition and Nasdaq audit committee non-compliance

## Summary
- Dr. Han Ying appointed CEO effective Jan 15, 2024, succeeding retired Dr. Charles Wu.
- Employment agreement: $350K base salary, annual bonus, severance with 12-month salary, COBRA, and equity acceleration.
- Audit committee vacancy after Ying's departure; Nasdaq notified of non-compliance with Listing Rule 5605.
- Cure period runs until earlier of next annual meeting or July 15, 2024 to restore compliance.
- Dr. Renate Parry appointed Chair of Compensation Committee, replacing Dr. Han Ying.

## SEC filing metadata
- accession: 0001140361-24-002903
- form_type: 8-K/A
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2024-01-19T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/0001140361-24-002903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/ef20019132_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-002903
- JSON: https://secwatch.observer/filing/0001140361-24-002903.json
- Plain text: https://secwatch.observer/filing/0001140361-24-002903.txt

## Key facts
- Listing & Compliance Notices
  GYRE THERAPEUTICS, INC. received a nasdaq noncompliance notice notice regarding audit committee (rules 5605).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: audit committee
  - Rules: 5605
  source text: January 17, 2024, the Company received a letter from Nasdaq confirming that t he Company is no longer in compliance with Nasdaq’s audit committee composition requirements as set forth in Nasdaq Listing Rule 5605, which requires that the audit committee of a listed company be comprised of at least three “independent directors” (as defined in Nasdaq Listing Rule 5605(a)(2)) . Pursuant to Nasdaq Listing Rule 5605(c)(4), the Company intends to rely on the cure period to reestablish compliance with Nasdaq Listing Rule 5605. The cure period is generally defined as until the earlier of the Company’
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/0001140361-24-002903-index.htm
- Executive change
  Dr. Han Ying changed role as Chair of Compensation Committee at GYRE THERAPEUTICS, INC..
  - Action: stepped down
  - Role: Chair of Compensation Committee
  source text: Dr. Han Ying, who stepped down as Chair and member of such committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/0001140361-24-002903-index.htm
- Executive change
  Dr. Han Ying was appointed as Chief Executive Officer at GYRE THERAPEUTICS, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On January 15, 2024, the Company entered into an employment agreement with Dr. Ying (the “Employment Agreement”) to serve as the Company’s Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/0001140361-24-002903-index.htm
- Executive change
  Dr. Han Ying changed role as Member of Audit Committee at GYRE THERAPEUTICS, INC..
  - Action: stepped down
  - Role: Member of Audit Committee
  source text: On January 15, 2024, Dr. Ying stepped down as a member of the Board’s Audit Committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/0001140361-24-002903-index.htm
- Executive change
  Dr. Renate Parry was appointed as Chair of Compensation Committee at GYRE THERAPEUTICS, INC..
  - Action: appointed
  - Role: Chair of Compensation Committee
  source text: Effective as of January 15, 2024, the Board appointed Dr. Renate Parry as Chair of the Board’s Compensation Committee, replacing Dr. Han Ying
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/0001140361-24-002903-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.